Introduction
Enterprise Milestone

2011 YEAR ~ Present

  • Apr 2018

    We further acquired the remaining 40% equity interest in Hefei City Guozhen Pharmaceutical Sales Limited, which became a 100% owned subsidiary

  • Aug 2016

    We further acquired the remaining 49% equity interest in Heilongjiang Tongze, which became a 100% owned subsidiary

  • Dec 2014

    Cooperates with MicroBase Technology Corp. Co-developing New Drug Device Combination Products for Respiratory Therapy

  • Aug 2014

    Acquired 60% of Auspicious Day Group Limited and its subsidiary Hai Nan Quan Yuan Pharmaceutical Company Limited.

  • Mar 2014

    Establish Shechen Pharmaceutical Ltd. jointly with Pharmadax Inc for the development and sale of medicines.

  • Jan 2014

    Obtained the distribution right of joint devices from Mattys Swiss in northern China.
    Obtained the distribution right of Wulusa-a medicine for the treatment of liver desease casused by Cholestasis in 10 provinces in China from Daewoong Pharmaceutical Co., Ltd.

  • Sep 2013

    Our 100% owned subsidiary Central Chief Limited acquired 60% of Exquisite Creation Limited 精創有限公司, which owned 100% of Hefei City Guozhen Pharmaceutical Sales Limited

  • Mar 2013

    Obtained the exclusive distribution right in China for Pfizer’s Detrol, for the treatment of overactive bladder (OBA).

  • Dec 2012

    Obtained exclusive distribution right for Pfizer’s Le Zhi Ping (lipid-lowering drugs) in China.

  • Jul 2012

    Wholly owned subsidiary Shanghai Guochuang Pharmaceutical Company Limited acquired 51% equity interest of Heilongjiang Province Tongze Pharmaceutical Company Limited by cash.

  • Oct 2011

    Stocks listed on the Taiwan Stock Exchange (stock code: 4144).
    Established the subsidiary, Coland Development Stock Company Limited.

  • Sep 2011

    Conducted IPO

  • Feb 2011

    Conducted increase of capital by cash injection by the Company.
    Obtained China’s exclusive distribution right of Taiwan Biotech Company’s compound ipratropium bromide inhalation solution.

 

2003~2010YEAR

  • Sep 2010

    Obtained distribution right of orthopedic implants in certain designated hospitals in Shanghai fromMedtronics

  • Jul 2010

    Obtained China’s exclusive distribution right for the tiotropium bromide spray from Zhejiang Xianju Pharmaceutical Company Limited

  • May 2010

    Conducted increase of capital by cash injection by the Company

  • Apr 2010

    Share swap between Coland Holdings Limited and shareholders of Central Chief Limited so that Central Chief Limited become the Company’s 100% owned subsidiary

  • Mar 2010

    Coland Holdings Limited was established as the applicant for IPO in Taiwan.
    Business of Hainan Coland, Hainan Kang He and Hangzhou Sheng You reorganized into Shanghai Guochuang Pharmaceutical Company Limited.

  • Jan 2010

    With the approval from Shanghai Administration for Industry and Commerce for change of business license, Coland Group officially acquired 100% equity interest in Shanghai Guochuang Pharmaceutical Company Limited.

  • Dec 2009

    Shanghai Municipal Chamber of Commerce approved the acquisition of 100% equity interest in Shanghai Guochuang Pharmaceutical Company Limited by Coland Pharmaceutical Company Limited.

  • Sep 2009

    Central Chief Limited resolved to establish Coland Pharmaceutical Company Limited in Hong Kong as the window and bridge among China, Hong Kong and Taiwan.

  • Jul 2009

    Central Chief Limited as established as the group’s investment holding company

  • Aug 2008

    Sales of hepatitis medicine reached approximately 50 million pills

  • Aug 2006

    Established Hainan Kang He Pharmaceutical Company Limited

  • Jul 2005

    Hepatitis medicine was approved as China’s class one new drug and successfully launched to the market.

  • Jan 2005

    Established Hainan Coland Pharmaceutical Company Limited

  • Apr 2003

    Established R&D Institution – Hangzhou Sheng You Medical Technology Development Company Limited, cooperated with Tianjin Institute of Pharmaceutical Research to develop medicines for the treatment of hepatitis

?
女上男下边做边叫视频